EMAIL DETAILS

Hi Bob,

It was great to catch up last week. We would appreciate it if you could
provide introductions to the companies discussed during our meeting as
appropriate. Also, please feel free to visit Hunter and the rest of our
business development team whenever you have time on a trip to D.C.

As discussed during our meeting, since closing the investment in Counsyl
RSTP's business development team has been working closely with the company
to help them expand their business in key geographies. Counsyl had a great
2011 and strong momentum in Q4. Some highlights include:

*2011 Highlights*

- 22,400 people screened
- 1,270 clinics and hospitals have ordered the UGT as of 12/31/2011
- 15% increase in requisition value YoY ($435 to $500)
- Introduction of Fragile X screening
- Requisition revenue of $11.2 million, 533% growth YoY
- Annual gross margin of 65.5%
- Invoiced revenue grew 800% from $200k in January to $1.6 million in
December
- Invoiced revenue run rate of $20 million as of December

*Q4 Highlights:*

- Gross margins were 70.5% in Q4, increasing from 34% in Q1
- 10,492 people screened in Q4, representing requisition growth of 65%
QoQ
- Requisition revenue of $5.6 million, an increase of 81% QoQ
- Raised $28 million Series B round and completed $5 million venture
debt financing
- Cash flow positive in Q4
- Signed 6 year lease on 27,000 square foot facility in South San
Francisco
- Increased sales team to 34 people

Counsyl expects strong growth and continued profitability in 2012. The
Company expects its new lab to be fully operational by April, 2012 and to
be state of the art in terms of automation which will have a positive
impact on gross margins. The company is hiring aggressively for key sales,
marketing and lab positions.

Please feel free to call me with any questions.

My best,

John

John DeLoche
*Managing Director*
Rosemont Seneca Technology Partners
One Market, Spear Tower, 36th Floor
San Francisco, CA 94105
office: 415 293 8147
mobile: 415 793 7070

This email communication is privileged and confidential and is intended
only for the individuals or entities named above. Any unauthorized
dissemination of any of the contents of this email is strictly prohibited.
If you are not the intended recipient, please do not read, copy, use or
disclose to others the contents of this communication. Please notify the
sender that you have received this e-mail in error and then delete the
e-mail